Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederema.europa.eu
What's new
Get the latest updates from What's new directly as they happen.
Follow now 326 followers
Latest posts
Last updated 2 minutes ago
Expert panel support for breakthrough medical devices: pilot programme
6 minutes ago
Expert panel support for breakthrough medical devices: pilot programme
Breakthrough status request: Template for applicants for breakthrough medical devices pilot
8 minutes ago
Breakthrough status request: Template for applicants for breakthrough medical devices pilot
CVMP Interested Parties’ meeting 2026, European Medicines Agency, Amsterdam, the Netherlands, from 20 May 2026, 17:00 (CEST) to 20 May 2026, 19:00 (CEST)
10 minutes ago
CVMP Interested Parties’ meeting 2026, European Medicines Agency, Amsterdam, the Netherlands, from...
Advice request: Template for applicants for breakthrough medical devices pilot
10 minutes ago
Advice request: Template for applicants for breakthrough medical devices pilot
Draft reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Revision 1
about 1 hour ago
Draft reflection paper on the use of macrolides, lincosamides and streptogramins (MLS)...
Use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health - Scientific guideline
about 1 hour ago
Use of macrolides, lincosamides and streptogramins (MLS) in animals in the European...
Human medicines European public assessment report (EPAR): Vysribli (previously Denosumab Intas), Vysribli, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised
about 1 hour ago
Human medicines European public assessment report (EPAR): Vysribli (previously Denosumab Intas), Vysribli...
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0497/2022
about 18 hours ago
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, risankizumab, decision type: PM...
Human medicines European public assessment report (EPAR): Terrosa, teriparatide, Date of authorisation: 04/01/2017, Revision: 8, Status: Authorised
about 18 hours ago
Human medicines European public assessment report (EPAR): Terrosa, teriparatide, Date of authorisation...
Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Date of authorisation: 15/07/2022, Revision: 12, Status: Authorised
about 18 hours ago
Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Date of authorisation...
Human medicines European public assessment report (EPAR): Jayempi, azathioprine, Date of authorisation: 21/06/2021, Revision: 9, Status: Authorised
about 18 hours ago
Human medicines European public assessment report (EPAR): Jayempi, azathioprine, Date of authorisation...
Human medicines European public assessment report (EPAR): Aptivus, tipranavir, Date of authorisation: 25/10/2005, Revision: 44, Status: Authorised
about 19 hours ago
Human medicines European public assessment report (EPAR): Aptivus, tipranavir, Date of authorisation...